Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

2,5-DIMETHOXY-4-METHYLAMPHETAMINE (DOM), A NEUROPHARMACOLOGICAL EXAMINATION

MARSHALL B. WALLACH, EITAN FRIEDMAN and SAMUEL GERSHON
Journal of Pharmacology and Experimental Therapeutics July 1972, 182 (1) 145-154;
MARSHALL B. WALLACH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EITAN FRIEDMAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SAMUEL GERSHON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The neuropharmacology of 2,5-dimethoxy-4-methylamphetamine (DOM) was examined. A single 8 mg/kg dose of DOM elicits electroencephalogram hypersynchrony and elevates reticular formation multiple unit activity. A second dose, 24 hours later, is without effect. The behavioral effects of a single dose of DOM are antagonized by methysergide, brom-lysergic acid diethylamide (brom-LSD), chlorpromazine and tripelennamine, but not by reserpine, α-methyl-p-tyrosine, p-chlorophenylalanine, phenoxybenzarnine, propranolol, atropine and diphenhydramine. Cyproheptadine was weakly antagonistic. Methysergide and brom-LSD induced intermittent hypersynchrony in the electroencephalogram and prevented the continuous hypersynchrony induced by DOM. DOM caused an increase in medullary norepinephrine and a slight increase of serotonin in the diencephalon and cerebral hemispheres. A second dose of DOM again increased the medullary norepinephrine but reduced diencephalic serotomn. DOM induces hypersynchrony and behavioral changes similar to those induced by perception distorting psychotomimetic drugs such as LSD and mescaline. It does not induce the electroencephalogram desynchronization or stereotyped behavior previously described for amphetamine. DOM appears to act on postsynaptic serotonin receptors.

Footnotes

    • Received October 18, 1971.
    • Accepted April 7, 1972.
  • © 1972, by The Williams & Wilkins Company

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 182, Issue 1
1 Jul 1972
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
2,5-DIMETHOXY-4-METHYLAMPHETAMINE (DOM), A NEUROPHARMACOLOGICAL EXAMINATION
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

2,5-DIMETHOXY-4-METHYLAMPHETAMINE (DOM), A NEUROPHARMACOLOGICAL EXAMINATION

MARSHALL B. WALLACH, EITAN FRIEDMAN and SAMUEL GERSHON
Journal of Pharmacology and Experimental Therapeutics July 1, 1972, 182 (1) 145-154;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

2,5-DIMETHOXY-4-METHYLAMPHETAMINE (DOM), A NEUROPHARMACOLOGICAL EXAMINATION

MARSHALL B. WALLACH, EITAN FRIEDMAN and SAMUEL GERSHON
Journal of Pharmacology and Experimental Therapeutics July 1, 1972, 182 (1) 145-154;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PST3093 Stimulates SERCA2a and Improves Cardiac Function
  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Evidence That Melanocortin 4 Receptor Mediates Hemorrhagic Shock Reversal Caused by Melanocortin Peptides
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics